John Harris joins OET as Chair of the Board of Directors

Oxford Expression Technologies is delighted to welcome John Harris as Chair of the Board of Directors.

John brings to OET extensive leadership, Board, and managerial competence developed within well respected Blue-Chip, Governmental and SME organisations specialised in the Life Sciences Sectors. Over his 37 years working in this space (including 23 years at CEO level), he has developed considerable experience and expertise within the Biotech, pharmaceutical and medical technology arenas ranging through research, technical & commercial development, registration, manufacture, marketing, and sales.

Prior to joining OET as Chair, John remains as the CEO of OBN Group until the end of April 2022, the largest & most innovative Life Sciences membership organisation in the UK with over 400 member companies located across the Golden Triangle of Oxford, London, Cambridge and beyond.

Previous appointments include Managing Partner of LifeAgility Associates, a specialist consultancy focused on strategy and business support for Life Sciences SME’s, Managing Director of IPS Specials (a cGMP, MHRA licensed manufacturer of pharmaceuticals), Managing Director of Key Organics Ltd (a leading manufacturer of chemical intermediates), Managing Director of Synerga Ltd (a start-up drug discovery venture), Chairman & CEO of TraceTag International Ltd (a biotech company specialising in hi-tech diagnostics), Managing Director of AgriSense-BCS (specialist biorationals manufacturer), and senior management roles in Zeneca, Novo Nordisk (Denmark), Monsanto (Belgium), and Shell.

Robert Possee, co-founder and CEO of OET, said:

‘We are delighted that John is joining us at an exciting time for OET. As we move into our next phase of development, John’s wealth of experience and expertise in the sector will ensure that OET is able to maximise its potential under sound leadership.’

John Harris, new Chair of OET, said:

‘It is an immense pleasureand privilege to take on the Chair role and become part of the team. OET’s proprietary technology and expertise in protein expression ideally positions the company to exploit the growth in Biotech and vaccine technologies, and I look forward to assisting and supporting the Management Team as they seek to leverage these opportunities to the maximum.’

John will take up his new post in January 2022.